Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Position Decreased by Federated Hermes Inc.

Federated Hermes Inc. decreased its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) by 54.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 333,785 shares of the biopharmaceutical company’s stock after selling 395,565 shares during the period. Federated Hermes Inc. owned approximately 0.20% of Sangamo Therapeutics worth $1,637,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Nuveen Asset Management LLC lifted its stake in Sangamo Therapeutics by 208.4% during the third quarter. Nuveen Asset Management LLC now owns 3,355,829 shares of the biopharmaceutical company’s stock valued at $16,444,000 after buying an additional 2,267,632 shares in the last quarter. BlackRock Inc. lifted its stake in Sangamo Therapeutics by 15.4% during the third quarter. BlackRock Inc. now owns 14,264,458 shares of the biopharmaceutical company’s stock valued at $69,894,000 after buying an additional 1,898,292 shares in the last quarter. State Street Corp lifted its stake in Sangamo Therapeutics by 25.3% during the first quarter. State Street Corp now owns 7,775,327 shares of the biopharmaceutical company’s stock valued at $45,175,000 after buying an additional 1,570,740 shares in the last quarter. Casdin Capital LLC purchased a new stake in Sangamo Therapeutics during the second quarter valued at about $4,140,000. Finally, Vanguard Group Inc. lifted its stake in Sangamo Therapeutics by 8.5% during the first quarter. Vanguard Group Inc. now owns 10,135,861 shares of the biopharmaceutical company’s stock valued at $58,890,000 after buying an additional 795,306 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

Sangamo Therapeutics Trading Down 1.7 %

Shares of SGMO stock opened at $2.26 on Friday. Sangamo Therapeutics, Inc. has a 12 month low of $2.13 and a 12 month high of $6.42. The business’s 50 day moving average is $3.17 and its two-hundred day moving average is $3.92.

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.04. Sangamo Therapeutics had a negative return on equity of 61.19% and a negative net margin of 172.76%. The company had revenue of $27.23 million for the quarter, compared to the consensus estimate of $26.86 million. During the same quarter last year, the company posted ($0.26) earnings per share. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. As a group, research analysts forecast that Sangamo Therapeutics, Inc. will post -1.29 EPS for the current year.

Analysts Set New Price Targets

SGMO has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their price target on shares of Sangamo Therapeutics from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, January 4th. Wedbush raised shares of Sangamo Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Monday, February 27th. Bank of America downgraded Sangamo Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $8.00 to $5.00 in a report on Friday, January 6th. Royal Bank of Canada dropped their price objective on Sangamo Therapeutics from $22.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, February 23rd. Finally, HC Wainwright dropped their price objective on Sangamo Therapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, March 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $13.83.

Sangamo Therapeutics Profile

(Get Rating)

Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.